Trial Profile

TST-004 for treatment of IgA Nephropathy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TST 004 (Primary)
Indications IgA nephropathy
Focus Adverse reactions

Most Recent Events

11 Oct 2022 New trial record
04 Oct 2022 According to Transcenta media release, the company has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (U.S FDA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com